Bernie Sanders urges Denmark for price pressure

US Senator Bernie Sanders has penned an op-ed in Politiken calling on the Danish people to encourage Novo Nordisk to lower the prices of diabetes drugs Ozempic and Wegovy, highlighting the significant price disparity between the US and countries like Germany. Sanders acknowledges the drugs’ potential to change the game for individuals worldwide but emphasizes the accessibility issue for those who cannot afford them. The high cost of these medications in the US could potentially bankrupt the country’s public health insurance programs, such as Medicare and Medicaid. A congressional committee launched an investigation into Novo Nordisk’s pricing of these drugs in April. Responding to the scrutiny, Novo Nordisk described the US pricing system as complex. While Sanders concurs that the pricing is indeed complex, he attributes the company’s pricing strategy in the US to nothing but greed.